Becaplermin
- Generic Name
- Becaplermin
- Brand Names
- Regranex
- Drug Type
- Biotech
- CAS Number
- 165101-51-9
- Unique Ingredient Identifier
- 1B56C968OA
- Background
Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.
- Indication
For topical treatment of skin ulcers (from diabetes)
- Associated Conditions
- Skin Ulcer
TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2008-05-07
- Lead Sponsor
- Solsys Medical LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00389636
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
Phase 3
Terminated
- Conditions
- Foot UlcerDiabetic FootSkin UlcerDiabetic Neuropathies
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 84
- Registration Number
- NCT00034788
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath